BRPI0510047A - composição farmacêutica, kit e método para tratar um indivìduo sofrendo de um distúrbio requerendo terapia de glicocorticóide aguda, e, uso de uma composição farmacêutica - Google Patents

composição farmacêutica, kit e método para tratar um indivìduo sofrendo de um distúrbio requerendo terapia de glicocorticóide aguda, e, uso de uma composição farmacêutica

Info

Publication number
BRPI0510047A
BRPI0510047A BRPI0510047-0A BRPI0510047A BRPI0510047A BR PI0510047 A BRPI0510047 A BR PI0510047A BR PI0510047 A BRPI0510047 A BR PI0510047A BR PI0510047 A BRPI0510047 A BR PI0510047A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
treating
kit
individual suffering
glucocorticoid
Prior art date
Application number
BRPI0510047-0A
Other languages
English (en)
Inventor
Stanko Skrtic
Joergen Johnsson
Hans Lennernos
Thomas Hedner
Gudmundur Johannsson
Original Assignee
Duocort Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0401032A external-priority patent/SE0401032D0/xx
Application filed by Duocort Ab filed Critical Duocort Ab
Publication of BRPI0510047A publication Critical patent/BRPI0510047A/pt
Publication of BRPI0510047B1 publication Critical patent/BRPI0510047B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

COMPOSIçãO FARMACêUTICA, KIT E MéTODO PARA TRATAR UM INDIVìDUO SOFRENDO DE UM DISTúRBIO REQUERENDO TERAPIA DE GLICOCORTICóIDE AGUDA, E, USO DE UMA COMPOSIçãO FARMACêUTICA. A presente invenção refere-se às composições farmacêuticas contendo glicocorticóide ou aos kits para uso em situações emergenciais agudas nas quais terapia de glicocorticóide aguda é requerida. Notavelmente, a invenção refere-se às composições farmacêuticas e aos kits que são planejados para serem administrados por pessoas não-medicalmente treinadas fora de um hospital ou outro ambiente clínico ou médico. A invenção também se refere a um método para tratar uma doença requerendo terapia de glicocorticóide aguda pela provisão de um início rápido de ação de um glicocorticóide.
BRPI0510047-0A 2004-04-22 2005-04-21 Composições farmacêuticas na forma de filme de camada única de liberação imediata de prednisolona ou hidrocortisona BRPI0510047B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US56420604P 2004-04-22 2004-04-22
US60/564,206 2004-04-22
SE0401032-8 2004-04-22
SE0401032A SE0401032D0 (sv) 2004-04-22 2004-04-22 A new acute glucocorticoid therapy
PCT/EP2005/004399 WO2005102287A2 (en) 2004-04-22 2005-04-21 Pharmaceutical compositions for acute glucocorticoid therapy

Publications (2)

Publication Number Publication Date
BRPI0510047A true BRPI0510047A (pt) 2007-10-16
BRPI0510047B1 BRPI0510047B1 (pt) 2023-07-11

Family

ID=

Also Published As

Publication number Publication date
JP2013010804A (ja) 2013-01-17
JP2007533697A (ja) 2007-11-22
US20090035375A1 (en) 2009-02-05
NZ551336A (en) 2010-04-30
EP2468266A2 (en) 2012-06-27
CA2563609A1 (en) 2005-11-03
IL178775A0 (en) 2007-02-11
EP2468266A3 (en) 2012-10-24
AU2005235369A1 (en) 2005-11-03
MXPA06012088A (es) 2007-08-14
AU2005235369B2 (en) 2010-11-11
PL1744760T3 (pl) 2015-04-30
EP1744760B1 (en) 2015-01-07
EP1744760A2 (en) 2007-01-24
WO2005102287A3 (en) 2006-06-22
CA2563609C (en) 2012-11-06
US9925139B2 (en) 2018-03-27
WO2005102287A2 (en) 2005-11-03
IL178775A (en) 2015-10-29

Similar Documents

Publication Publication Date Title
WO2005102287A3 (en) Pharmaceutical compositions for acute glucocorticoid therapy
BR112022010349A2 (pt) Compostos bifuncionais para degradar btk por meio de via da ubiquitina-proteossoma
BR112022001413A2 (pt) Preparação de canabidiol, e, método para tratar uma modificação da doença em um paciente que sofre de síndrome de dravet
BRPI0611717A2 (pt) composto, composiÇço farmacÊutica e uso do composto
BR112012012610A2 (pt) terapia de combinação para o tratamento de câncer e ensaios diagnósticos para o uso na mesma
BR112014014181A2 (pt) combinação de ozogamicina inotuzumab e torisel para o tratamento de câncer
BRPI0410503B8 (pt) composição tópica e uso da composição
BRPI0609393B8 (pt) usos de um composto 11-desóxi-prostaglandina
BRPI0912411A8 (pt) uso de uma muteína de interleucina humana-2 (muteína de hil-2) ou de um fragmento da mesma, composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune, uso de muteína de interleucina humana-2 (muteína de hil-2) ou de uma seção da mesma, agete para formação de células t regulatórias (treg) em um organismo, método para tratamento e/ou profilaxia de uma doença autoimune em um organismo, método para formação de células t regulatórias (treg) em um organismo, método para formação de células t regulatórias (treg) in vitro.
BR112012001984B8 (pt) anticorpos humanos com alta afinidade para angiopoietina-2 humana, uso dos mesmos e composição farmacêutica
BR112013010021A2 (pt) combinações farmacêuticas para o tratamento de distúrbios metabólicos.
BRPI0511139A (pt) compostos, composição farmacêutica que compreende os mesmos, método para inibir atividade de quinase aurora em uma célula e método para tratamento de um distúrbio mediado por quinase aurora em um paciente
NO20065442L (no) Amidoforbindelser og deres anvendelse som legemidler
BRPI0622054B8 (pt) composto e composição farmacêutica
BR122013013162A2 (pt) Uso de rivastigmina para preparar um sistema terapêutico transdérmico (tts)
DOP2009000269A (es) Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
EA200900203A1 (ru) Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение
BRPI0616962B8 (pt) uso de lactobacillus para o tratamento de doenças autoimunes
CO6390109A2 (es) Inhibidores de syk de imidazopirazina
DOP2007000053A (es) Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo
BR112014010417A2 (pt) Métodos para o tratamento de cânceres com o uso de formulações orais de análogos de citidina
WO2007103373A3 (en) Compositions and methods for the treatment of immunoinflammatory disorders
BR112012022552A8 (pt) uso de fenoterol e de análogos de fenoterol no tratamento de gliobastomas e astrocitomas e composição farmacêutica compreendendo os referidos compostos
BRPI0411295A (pt) compostos e seu uso na terapia
BR112013008573A2 (pt) citocinas biomarcadoras como indicadores de resposta clínica a acetato de glatirâmer.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: ACUCORT AB (SE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/04/2005, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2876 DE 18/02/2026 POR TER SIDO INDEVIDA.